Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $5.7799 (-3.82%) ($5.7400 - $6.1250) on Wed. Jun. 10, 2020. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 7.96% (three month average) | RSI | 60 | Latest Price | $5.7799(-3.82%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.2% a day on average for past five trading days. | Market Behavior | Value stocks sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) XBI(29%) ARKG(28%) ARKK(27%) ACES(25%) IBB(25%) | Factors Impacting HTBX price | HTBX will decline at least -3.98% in a week (0% probabilities). VXX(-17%) VIXM(-13%) UUP(-11%) UNG(-7%) XLP(-3%) | | | | | Relative Volatility | | | | Market Trend Strength | -3.98% (StdDev 7.96%) | Hourly BBV | 0 () | Intraday Trend | -5.4% | | | |
|
5 Day Moving Average | $6.03(-4.15%) | 10 Day Moving Average | $6.26(-7.67%) | 20 Day Moving Average | $5.77(0.17%) | To recent high | -25.6% | To recent low | 11.2% | Market Cap | $636m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |